• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Vigil Neuroscience Inc.

    5/30/25 5:04:30 PM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VIGL alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Vigil Neuroscience, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    92673K108

    (CUSIP Number)


    05/22/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    92673K108


    1Names of Reporting Persons

    Beryl Capital Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,606,267.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,606,267.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,606,267.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:  Percentage calculated based on 46,671,534 shares of Common Stock outstanding on April 30, 2025, as disclosed in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2025.


    SCHEDULE 13G

    CUSIP No.
    92673K108


    1Names of Reporting Persons

    Beryl Capital Management LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,606,267.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,606,267.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,606,267.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IA, PN

    Comment for Type of Reporting Person:  Percentage calculated based on 46,671,534 shares of Common Stock outstanding on April 30, 2025, as disclosed in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2025.


    SCHEDULE 13G

    CUSIP No.
    92673K108


    1Names of Reporting Persons

    Beryl Capital Partners II LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,711,724.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,711,724.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,711,724.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.0 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Percentage calculated based on 46,671,534 shares of Common Stock outstanding on April 30, 2025, as disclosed in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2025.


    SCHEDULE 13G

    CUSIP No.
    92673K108


    1Names of Reporting Persons

    David A. Witkin
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,606,267.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,606,267.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,606,267.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  Percentage calculated based on 46,671,534 shares of Common Stock outstanding on April 30, 2025, as disclosed in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Vigil Neuroscience, Inc.
    (b)Address of issuer's principal executive offices:

    100 Forge Road, Suite 700, Watertown, MA 02472
    Item 2. 
    (a)Name of person filing:

    Beryl Capital Management LLC, a Delaware limited liability company ("Beryl") Beryl Capital Management LP, a Delaware limited partnership ("Beryl GP") Beryl Capital Partners II LP, a Delaware limited partnership (the "Partnership") David A. Witkin Each reporting person disclaims beneficial ownership of Common Stock except to the extent of that person's pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any Common Stock covered by this Schedule 13G.
    (b)Address or principal business office or, if none, residence:

    225 Avenue I, Suite 205 Redondo Beach, CA 90277
    (c)Citizenship:

    See Item 4 of the cover sheet for each reporting person.
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    92673K108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Beryl: 4,606,267 Beryl GP: 4,606,267 Partnership: 3,711,724 David A Witkin: 4,606,267
    (b)Percent of class:

    Beryl: 9.9% Beryl GP: 9.9% Partnership: 8.0% David A. Witkin: 9.9%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Beryl: 0 Beryl GP: 0 Partnership: 0 David A. Witkin: 0

     (ii) Shared power to vote or to direct the vote:

    Beryl: 4,606,267 Beryl GP: 4,606,267 Partnership: 3,711,724 David A Witkin: 4,606,267

     (iii) Sole power to dispose or to direct the disposition of:

    Beryl: 0 Beryl GP: 0 Partnership: 0 David A. Witkin: 0

     (iv) Shared power to dispose or to direct the disposition of:

    Beryl: 4,606,267 Beryl GP: 4,606,267 Partnership: 3,711,724 David A Witkin: 4,606,267

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    Beryl is the investment adviser to the Partnership and other accounts. Beryl is the general partner of Beryl GP, which is the general partner of the Partnership and other private investment funds. Mr. Witkin is the control person of Beryl.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Beryl Capital Management LLC
     
    Signature:/s/ Andrew Nelson
    Name/Title:Chief Operating Officer
    Date:05/30/2025
     
    Beryl Capital Management LP
     
    Signature:/s/ Andrew Nelson
    Name/Title:Chief Operating Officer of Beryl Capital Management LLC, General Partner of Beryl Capital Management LP
    Date:05/30/2025
     
    Beryl Capital Partners II LP
     
    Signature:/s/ Andrew Nelson
    Name/Title:COO of Beryl Capital Management LLC, General Partner of Beryl Capital Management LP, General Partner of Beryl Capital Partners II LP
    Date:05/30/2025
     
    David A. Witkin
     
    Signature:/s/ David A. Witkin
    Name/Title:Reporting person
    Date:05/30/2025
    Exhibit Information

    Exhibit 99.1 - Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G

    Get the next $VIGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VIGL

    DatePrice TargetRatingAnalyst
    5/28/2025$8.00Buy → Hold
    Stifel
    12/4/2024Outperform
    William Blair
    12/19/2023$13.00 → $4.00Equal-Weight → Underweight
    Morgan Stanley
    10/18/2023$23.00Mkt Outperform
    JMP Securities
    3/31/2023$15.00Buy
    Mizuho
    9/16/2022$19.00Outperform
    Wedbush
    8/29/2022$24.00Buy
    H.C. Wainwright
    2/1/2022$17.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $VIGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Booth Bruce was granted 5,000 shares (SEC Form 4)

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      5/23/25 8:46:39 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Vitorovic Stefan was granted 5,000 shares (SEC Form 4)

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      5/23/25 8:45:31 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Bruhn Suzanne Louise was granted 5,000 shares (SEC Form 4)

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      5/23/25 8:44:02 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Vigil Neuroscience Inc.

      SC 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

      11/14/24 4:19:18 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vigil Neuroscience Inc.

      SC 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

      11/14/24 10:00:07 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Vigil Neuroscience Inc.

      SC 13D/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

      10/9/24 6:22:58 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

      - Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer's disease – - Companies expect transaction to close in third quarter of 2025 - WATERTOWN, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for

      5/21/25 7:30:46 PM ET
      $SNY
      $VIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates

      – On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – – Plans to initiate Phase 2 clinical trial evaluating VG-3927 in Alzheimer's disease in Q3 2025 – WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the first quarter ending March 31, 2025, and provided updates on its recent progress. "During the quarter, we continued to make meaningful progress across our two TREM2 programs, VG-3927 and iluzanebart," said Ivana Ma

      5/7/25 7:00:00 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference

      - Preclinical presentation highlights key, modality specific, pharmacological differentiations of VG-3927 - - First presentation of topline clinical data from Phase 1 SAD/MAD trial of VG-3927 for the potential treatment of Alzheimer's disease (AD) - WATERTOWN, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented data highlighting its oral small molecule program, including its lead clinical candidate VG-3927, in two oral presentations at the AD/PD™ 2025 International Conference on Alzheimer's and Parkinson's Dis

      4/2/25 7:00:00 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    Leadership Updates

    Live Leadership Updates

    See more
    • Augustine Therapeutics appoints Gerhard Koenig as Chief Executive Officer as Company Prepares to Enter the Clinic

      Augustine Therapeutics appoints Gerhard Koenigas Chief Executive Officer as Company Prepares to Enter the Clinic Industry veteran Gerhard Koenig, PhD, current Executive Chairman, appointed as CEOBest-in-class highly selective HDAC6 inhibitor pioneer for disease-modifying treatment of neuromuscular, neurodegenerative and cardiometabolic diseases poised to enter the clinic LEUVEN, Belgium – February 13, 2025 – Augustine Therapeutics ("Augustine" or "the Company"), a preclinical-stage biotechnology company focused on innovative therapies for neuromuscular, neurodegenerative and cardiometabolic diseases through the inhibition of the cytosolic Histone DeACetylase 6 (HDAC6) enzyme, today announc

      2/13/25 7:00:00 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Augustine Therapeutics Raises EUR 17 Million in a Series A First Closing to Advance Lead Candidate Into Clinical Development in Neurological Diseases

      Proceeds will advance lead candidate AGT100216, a peripherally restricted and selective HDAC6 inhibitor, into a first-in-human clinical Phase 1/2 study Gerhard Koenig appointed as executive chairman of Augustine's Board of Directors Augustine Therapeutics, a pioneering biotech company focused on novel treatments for neurodegenerative and cardiometabolic diseases, today announced that it has raised EUR 17 million (USD 18.5 million) in the first closing of its Series A round. The financing was led by Asabys Partners, with participation from Eli Lilly and Company, and the US-based Charcot-Marie-Tooth Research Foundation. Current investors AdBio partners, V-Bio Ventures, PMV, VIB and Gem

      6/26/24 1:00:00 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update

      – Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer trial evaluating VG-3927 for Alzheimer's disease ongoing; Interim data analysis on track for mid-2024 – WATERTOWN, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent progress. "During the quarter, we continued to progress iluzanebart, our monoclonal antibody, and VG-3927, our or

      5/7/24 4:05:00 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Vigil Neuroscience Inc.

      SCHEDULE 13G - Vigil Neuroscience, Inc. (0001827087) (Subject)

      5/30/25 5:04:30 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Vigil Neuroscience Inc.

      8-K - Vigil Neuroscience, Inc. (0001827087) (Filer)

      5/23/25 5:26:03 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Vigil Neuroscience Inc.

      DEFA14A - Vigil Neuroscience, Inc. (0001827087) (Filer)

      5/22/25 4:36:58 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Budd Haeberlein Samantha L. bought $20,520 worth of shares (12,000 units at $1.71) (SEC Form 4)

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      12/19/24 6:44:11 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Magovcevic-Liebisch Ivana bought $8,400 worth of shares (5,000 units at $1.68), increasing direct ownership by 2% to 222,687 units (SEC Form 4)

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      12/19/24 6:42:45 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Magovcevic-Liebisch Ivana bought $8,350 worth of Common Stock (5,000 units at $1.67), increasing direct ownership by 2% to 217,687 units (SEC Form 4)

      4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

      12/18/24 5:51:48 PM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    Financials

    Live finance-specific insights

    See more
    • Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

      - Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer's disease – - Companies expect transaction to close in third quarter of 2025 - WATERTOWN, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for

      5/21/25 7:30:46 PM ET
      $SNY
      $VIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP

      VGL101 demonstrated favorable safety, tolerability and PK profiles in single ascending dose and multiple ascending dose cohortsVGL101 achieved dose dependent, robust and durable decreases in CSF sTREM2 demonstrating proof of target engagement further validating its mechanism of action On track to initiate Phase 2 trial with a 20 mg/kg dose of VGL101 in ALSP patients this quarterCompany to host conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced interim topline r

      11/2/22 7:00:00 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vigil Neuroscience downgraded by Stifel with a new price target

      Stifel downgraded Vigil Neuroscience from Buy to Hold and set a new price target of $8.00

      5/28/25 8:11:47 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • William Blair initiated coverage on Vigil Neuroscience

      William Blair initiated coverage of Vigil Neuroscience with a rating of Outperform

      12/4/24 7:51:48 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vigil Neuroscience downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Vigil Neuroscience from Equal-Weight to Underweight and set a new price target of $4.00 from $13.00 previously

      12/19/23 7:39:43 AM ET
      $VIGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care